Please Confirm

This website is an information resource intended only for Healthcare Professionals from U.S. who are interested in information on Clinical Research and EMD Serono clinical trials. 

By clicking “I am a healthcare professional” you are declaring and confirming that you are a Healthcare Professional inside the U.S. and have read and understood this disclaimer.

I AM NOT A HEALTHCARE PROFESSIONAL

Please Confirm

This website is an information resource intended only for Healthcare Professionals from U.S. who are interested in information on Clinical Research and EMD Serono clinical trials.

By clicking "I am a healthcare professional" you are declaring and confirming that you are a Healthcare Professional inside the U.S. and have read and understood this disclaimer.

OUR TRIALS

Welcome to our clinical trial platform informing about our research of tepotinib. Here, you will find information about tepotinib, an oral drug that blocks the activity of the MET protein in cells, which is currently being studied in clinical trials of cancer that has changes to the MET gene.

Tepotinib is under clinical investigation in various countries. The safety and efficacy of tepotinib must be investigated following the respective national regulations and laws. There is no guarantee that tepotinib will be approved in the sought-after indication by the health authority in your country.

 


Find out more about our tepotinib trials below

INSIGHT 2: Advanced/Metastatic NSCLC With MET amplification and Acquired Resistance to Osimertinib


Please Confirm

This website is an information resource intended only for Healthcare Professionals from U.S. who are interested in information on Clinical Research and EMD Serono clinical trials. 

By clicking “I am a healthcare professional” you are declaring and confirming that you are a Healthcare Professional inside the U.S. and have read and understood this disclaimer.

I AM NOT A HEALTHCARE PROFESSIONAL

LUNG

ADVANCED
METASTATIC

PHASE
2

COMBINATION
THERAPY

A phase 2 clinical study of tepotinib combined with osimertinib in patients with advanced or metastatic MET-amplified non-small cell lung cancer (NSCLC) with activating changes in the EGFR gene and resistance to prior osimertinib therapy

ClinicalTrials.gov: NCT03940703

Location: Asia, Europe, North America

Status:

NOW ENROLLING

US Medical Information: 888-275-7376 - eMediUSA@emdserono.com

Global Communication Center: +49 6151 72 5200 - service@emdgroup.com

Singapore Medical Information: +65 6890 6638 - medinfo_singapore@merckgroup.com

 

PERSPECTIVE: mCRC With Acquired Resistance to Anti-EGFR Therapy Due to MET Amplification


Please Confirm

This website is an information resource intended only for Healthcare Professionals from U.S. who are interested in information on Clinical Research and EMD Serono clinical trials. 

By clicking “I am a healthcare professional” you are declaring and confirming that you are a Healthcare Professional inside the U.S. and have read and understood this disclaimer.

I AM NOT A HEALTHCARE PROFESSIONAL

mCRC

ADVANCED
METASTATIC

PHASE
2

COMBINATION
THERAPY


A phase 2 clinical study of tepotinib combined with cetuximab* in patients with left-sided metastatic colorectcal cancer (mCRC) without changes in RAS/BRAF and with acquired resistance to anti-EGFR targeted antibody treatment due to MET amplification


Amplification
An increase in the number of copies of a gene.⁵

ClinicalTrials.gov: NCT04515394

Location: Europe, North America

Status:

NOW ENROLLING

US Medical Information: 888-275-7376 - eMediUSA@emdserono.com

Global Communication Center: +49 6151 72 5200 - service@emdgroup.com

 

*Cetuximab is not approved for use in combination with tepotinib in any indication


Amplification
An increase in the number of copies of a gene.⁵

 

VISION: Advanced/Metastatic NSCLC With MET Alterations


Please Confirm

This website is an information resource intended only for Healthcare Professionals from U.S. who are interested in information on Clinical Research and EMD Serono clinical trials. 

By clicking “I am a healthcare professional” you are declaring and confirming that you are a Healthcare Professional inside the U.S. and have read and understood this disclaimer.

I AM NOT A HEALTHCARE PROFESSIONAL

LUNG

ADVANCED
METASTATIC

PHASE
2

MONOTHERAPY

A phase 2 clinical study of tepotinib in patients with advanced (locally advanced or metastatic) non-small cell lung cancer (NSCLC) with changes in the MET gene.

ClinicalTrials.gov: NCT02864992

Location: Asia, Europe, North America

Status:

ACTIVE, NOT RECRUITING

US Medical Information: 888-275-7376 - eMediUSA@emdserono.com

Global Communication Center: +49 6151 72 5200 - service@emdgroup.com

Singapore Medical Information: +65 6890 6638 - medinfo_singapore@merckgroup.com

 

  1. National Cancer Institute. NCI Dictionary of Cancer Terms. Accessed June 11, 2021. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/metastatic
  2. National Cancer Institute. NCI Dictionary of Cancer Terms. Accessed June 11, 2021. https://www.cancer.gov/research/annual-plan/scientific-topics/drug-resistance
  3. National Cancer Institute. SEER Training Modules. Accessed June 11, 2021. https://training.seer.cancer.gov/colorectal/intro/types.html#:~:text=Left%2Dsided%20colon%20cancer%20typically,is%20low%20in%20the%20rectum
  4. Cancer.Net. Accessed June 11, 2021. https://www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/understanding-targeted-therapy
  5. National Cancer Institute. NCI Dictionary of Cancer Terms. Accessed June 11, 2021. https://www.cancer.gov/search/results?swKeyword=gene+amplification

Learn More About

Clinical Trials